Congratulations to David Vossler, MD, FANN, FACNS, FAES, Medical Director of Valley's Neuroscience Institute and his research teams who have announced the completion of their​ worldwide trial of lacosamide (Vimpat) for the treatment of "primary" generalized-onset tonic-clonic convulsive seizures. The results are published in the Journal of Neurology, Neurosurgery & Psychiatry.​

"Some of the patients were completely seizure free permanently, including two of ours here at VMC," says Dr. Vossler. "I fully believe this will be an important medication for the treatment of this severe seizure type which can lead to disability and death."

The project was started in 2010 with a proof of concept study and has finally reached completion with the Aug. 18, 2020 publication of the conclusive randomized clinical trial.

"Thank you to everyone here at Valley Medical Center for supporting Clinical Research," says Dr. Vossler. "Also, thank you to our colleagues at Rainier Clinical Research Center in Renton where these two trials were conducted!"